SIGNAL SWITCH RECEPTOR MODIFIED TIL

Clinical trials for SIGNAL SWITCH RECEPTOR MODIFIED TIL explained in plain language.

Never miss a new study

Get alerted when new SIGNAL SWITCH RECEPTOR MODIFIED TIL trials appear

Sign up with your email to follow new studies for SIGNAL SWITCH RECEPTOR MODIFIED TIL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Scientists re-engineer Patients' own immune cells to fight advanced gynecologic cancers

Disease control Recruiting now

This early-phase study is testing a new type of cell therapy called GC201 TIL for patients with advanced gynecologic tumors who have run out of standard treatment options. Doctors take a patient's own immune cells from a tumor sample, genetically modify them in the lab to better …

Matched conditions: SIGNAL SWITCH RECEPTOR MODIFIED TIL

Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control

Last updated Mar 23, 2026 15:15 UTC

SIGNAL SWITCH RECEPTOR MODIFIED TIL

Get alerted when new SIGNAL SWITCH RECEPTOR MODIFIED TIL trials appear

Scientists re-engineer Patients' own immune cells to fight advanced gynecologic cancers